Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. It specializes in blood volume measurement technology focused on blood volume testing innovation. It markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. It has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.
企業コードDXR
会社名Daxor Corp
上場日Jul 25, 1983
最高経営責任者「CEO」Mr. Michael Richard Feldschuh
従業員数- -
証券種類Ordinary Share
決算期末Jul 25
本社所在地Suite 7120
都市NEW YORK
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号10118
電話番号12122440555
ウェブサイトhttps://www.daxor.com/
企業コードDXR
上場日Jul 25, 1983
最高経営責任者「CEO」Mr. Michael Richard Feldschuh
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし